MycoBiomDB – Record Details (MyCo_2317)

Biomarker Record Details

Database ID: MyCo_2317
DB IDMyCo_2317
TitleRapid decrease of anti-beta-glucan antibody as an indicator for early diagnosis of carinii pneumonitis and deep mycotic infections following immunosuppressive therapy in antineutrophil cytoplasmic antibody-associated vasculitis
Year2009
PMID19190977
Fungal Diseases involvedCarinii Pneumonitis
Associated Medical ConditionPneumonia
GenusNone
SpeciesNone
OrganismNone
Ethical StatementNone
Site of InfectionNone
Opportunistic invasiveOpportunistic
Sample typeBody fluid
Sample sourcePlasma
Host GroupHuman
Host Common nameHuman
Host Scientific nameHomo sapiens
Biomarker Nameanti-β-glucan
Biomarker Full Nameanti-β-glucan
Biomarker TypePrognostic
BiomoleculeProtein
Geographical LocationJapan
CohortTwenty two healthy adults and 38 patients with AAV took part in the study.
Cohort No.60
Age GroupNone
P Valuep<0.05
SensitivityNone
SpecificityNone
Positive Predictive ValueNone
MICNone
Fold ChangeNone
PathwayNone
Disease Introduction MechanismSome patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) achieve a good outcome after immunosuppressive treatment consisting mainly of administration of corticosteroids and immunosuppressants; however, the mortality rate is high due to infection. It is therefore important to find an effective treatment for infection in AAV patients. Postmortem examination of four patients out of a total of 60 patients with AAV who had received immunosuppressive therapy showed mycosis (aspergillosis or cryptococcosis). This indicated the necessity for early diagnosis of deep mycosis and carinii pneumonitis infection.
TechniqueELISA
Analysis MethodELISA Based
ELISA kitsELISA KIT (Nunc 442404, F96 Maxisorp, Rochester,NY, USA)
Assay DataNone
Validation Techniques usedELISA
Up Regulation Down RegulationDecrease
Sequence DataNone
External LinkNone